Vaccines: Europe OK’s Novavax’s COVID-19 Vaccine Booster
The European Commission expanded theĀ approval of Novavax's COVID-19 vaccine as a booster for adults aged 18 and older.
The European Commission expanded theĀ approval of Novavax's COVID-19 vaccine as a booster for adults aged 18 and older.
Novavax Inc has received authorizations for its COVID-19 vaccine NVX-CoV2373 (brand name Nuvaxovid) in Great Britain and in New Zealand, the company reports.
Novavax Inc's COVID-19 vaccine candidate had a vaccine efficacy of 89.3% in a Phase 3 UK clinical trial, but appeared less effective (60%) against a South Africa variant.